Biliary Tract Cancer

Akeso reported that the 682-patient, randomized Phase III HARMONi-GI1 trial met its primary overall-survival endpoint at a prespecified interim analysis: ivonescimab plus gemcitabine and cisplatin produced a statistically significant and company-described clinically meaningful benefit…